Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other 2Gynecologic 1

Conditions

Constipation 6Intestinal Diseases 5Pain 3Neoplasms 2Opioid-Induced Constipation 1Cancer Pain 1

Interventions

Resistance Training 4Nutrition Assessment 4naloxegol 3Surveys and Questionnaires 3Exercise 3alvimopan 2Therapeutics 2Psychiatric Rehabilitation 2Oxygen 2Nutritional Status 2Mouthwashes 2Morphine 2Ketamine 2Interviews as Topic 2Fibroblast Growth Factor 7 2Counseling 2semaglutide 1naldemedine 1methylnaltrexone 1ma zi ren wan 1kang-lai-te 1hydrated silica gel-based toothpaste 1golotimod 1dexamethasone acetate 1dexamethasone 21-phosphate 1calcium phosphate 1auricularum 1aluminum hydroxide, magnesium hydroxide, drug combination 1Weights and Measures 1Walking 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × alvimopan × Other × Clear all
NCT00135577 2015-09-02

Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed
67 enrolled
Other

Opioid-Induced Constipation, Constipation, Intestinal Diseases, Neoplasms

NCT00331045 2015-09-02

Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Terminated
21 enrolled
Other

Constipation, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡